Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 9/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18998446 | 0.93 | THRB (0.40) | THRBRORCTHRAHTR2ASLC6A4 | |
| SCHEMBL18932876 | 0.88 | THRB (0.45) | THRBRORCHTR2ASLC6A4KCNH2 | |
| SCHEMBL282344 | 0.87 | THRB (0.59) | THRBRORCTHRAHTR2ASLC6A4 | |
| SCHEMBL4960799 | 0.84 | THRB (0.46) | THRBRORCTHRAHTR2ASLC6A4 | |
| SCHEMBL282509 | 0.83 | ATM (0.46) | THRBRORCTHRAHTR2ASLC6A4 | |
| SCHEMBL8892137 | 0.83 | MAPT (0.43) | THRBRORCTHRAHTR2ASLC6A4 | |
| SCHEMBL18918559 | 0.80 | THRB (0.48) | THRBRORCTHRA | |
| SCHEMBL18932877 | 0.79 | THRB (0.46) | THRBRORCTHRAHTR2ASLC6A4 | |
| SCHEMBL3152794 | 0.79 | THRA (0.43) | THRBTHRAHTR2AMEN1KMT2A | |
| SCHEMBL18932875 | 0.77 | THRB (0.55) | THRBRORCTHRAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181556-B1 | MICROMOLECULE COMPOUND, METHOD OF SYNTHESIS AND APPLICATION THEREOF | TECHNODERMA MEDICINES PTE LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
| EP-3181556-B1 | MICROMOLECULE COMPOUND, METHOD OF SYNTHESIS AND APPLICATION THEREOF | TECHNODERMA MEDICINES PTE LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-9920022-B2 | Small molecule compound and synthesizing method and uses thereof | TECHNODERMA MEDICINES PTE LTD. (CN) | 2018-03-20 | — | — | US | disclosed |
| US-9920022-B2 | Small molecule compound and synthesizing method and uses thereof | TECHNODERMA MEDICINES PTE LTD. (CN) | 2018-03-20 | — | — | US | disclosed |
| US-9920022-B2 | Small molecule compound and synthesizing method and uses thereof | TECHNODERMA MEDICINES PTE LTD. (CN) | 2018-03-20 | — | — | US | disclosed |
| EP-3181556-A1 | MICROMOLECULE COMPOUND, METHOD OF SYNTHESIS AND APPLICATION THEREOF | Technoderma Medicines Pte Ltd (CN) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181556-A1 | MICROMOLECULE COMPOUND, METHOD OF SYNTHESIS AND APPLICATION THEREOF | Technoderma Medicines Pte Ltd (CN) | 2017-06-21 | — | — | EP | disclosed |
| US-20170158651-A1 | SMALL MOLECULE COMPOUND AND SYNTHESIZING METHOD AND USES THEREOF | TECHNODERMA MEDICINES PTE LTD. | 2017-06-08 | — | — | US | disclosed |
| US-20170158651-A1 | SMALL MOLECULE COMPOUND AND SYNTHESIZING METHOD AND USES THEREOF | TECHNODERMA MEDICINES PTE LTD. | 2017-06-08 | — | — | US | disclosed |
| US-20170158651-A1 | SMALL MOLECULE COMPOUND AND SYNTHESIZING METHOD AND USES THEREOF | TECHNODERMA MEDICINES PTE LTD. | 2017-06-08 | — | — | US | disclosed |
| US-5654468-A | ANTILIPID, ANTICHOLESTEROL AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5569674-A | ANTICHOLESTEROL AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-10-29 | — | — | US | disclosed |
| US-5401772-A | Anticholesterol agents with aromatic amines | CIBA-GEIGY CORPORATION (US) | 1995-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158651-A1 | SMALL MOLECULE COMPOUND AND SYNTHESIZING METHOD AND USES THEREOF | MKI67, ACP1, TYR | THRB 2396/4885RORC 2654/4885THRA 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.